Comment from Frakes Kyle

Summary: Kyle Frakes, Founder of Moonlight Longevity, supports the inclusion of TB-500 on the Section 503A Bulk Drug Substances List to ensure continued access for wound healing and tissue repair. He argues that TB-500 addresses a significant unmet clinical need for chronic wounds and has a favorable safety profile based on preclinical and clinical evidence.